PFM
IMVT icon

Privium Fund Management’s Immunovant IMVT Stock Holding History

Privium Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,000
Closed -$1.23M – 59
2025
Q1 		$1.23M Buy
+72,000
New +$1.51M 0.32% 30

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Privium Fund Management's IMVT Position: Q2 2025 in Review

Privium Fund Management sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 72,000 shares — an estimated $1.23M sold.

Privium Fund Management first reported a position in IMVT in Q1 2025 and held it in 1 quarter. The position peaked at $1.23M in Q1 2025. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Privium Fund Management reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Privium Fund Management sold 72,000 Immunovant shares in Q2 2025, an estimated $1.23M.
  • Privium Fund Management first reported a position in Immunovant in Q1 2025 and held it in 1 quarter.
  • Privium Fund Management's Immunovant position peaked at $1.23M in Q1 2025.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Privium Fund Management's 13F filing for Q2 2025, filed 30 Jul 2025.